IP Library Granted Patent US 7,067,655
Granted Patent B2
US 7,067,655 · App. 10/912,834 · Granted Jun 27, 2006

Adenosine A2a receptor antagonists

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,067,655
App. No.
10/912,834
Granted
Jun 27, 2006
Kind
B2
Abstract

Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, cycloalkenyl, or heteroaryl; X is alkylene or —C(O)CH 2 —; Y is —N(R 2 )CH 2 CH 2 N(R 3 )—, —OCH 2 CH 2 N(R 2 )—, —O—, —S—, —CH 2 S—, —(CH 2 ) 2 —NH—, or optionally substituted m and n are 2–3, and Q is nitrogen or optionally substituted carbon; and Z is optionally substituted phenyl, phenylalkyl or heteroaryl, diphenylmethyl, R 6 —C(O)—, R 6 —SO 2 —, R 6 —OC(O)—, R 7 —N(R 8 )—C(O)—, R 7 —N(R 8 )—C(S)—, phenyl-CH(OH)—, or phenyl-C(═NOR 2 )—; or when Q is CH, phenylamino or pyridylamino; or Z and Y together are substituted piperidinyl or substituted phenyl; and R 2 , R 3 , R 6 , R 7 , and R 8 are as defined in the specification are disclosed, their use in the treatment of Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them; also disclosed are a processes for preparing intermediates useful for preparing compounds of formula I.

Claims (28)

1. A process of preparing a compound of formula II

wherein R is R 1 -furanyl, R 1 -thienyl, R 1 -pyridyl, R 1 -pyridyl N-oxide, R 1 -oxazolyl, R 10 -phenyl, R 1 -pyrrolyl or C 4 –C 6 cycloalkenyl;

R 1 is 1 to 3 substituents independently selected from hydrogen, C 1 –C 6 -alkyl, —CF 3 , halogen, —NO 2 , NR 12 R 13 , C 1 –C 6 alkoxy, C 1 –C 6 alkylthio, C 1 –C 6 alkylsulfinyl, and C 1 –C 6 alkylsulfonyl;

R 10 is 1 to 5 substituents independently selected from the group consisting of hydrogen, halogen, C 1 –C 6 alkyl, hydroxy, C 1 –C 6 alkoxy, —CN, —NH 2 , C 1 –C 6 alkylamino, di-((C 1 –C 6 )alkyl)amino, —CF 3 , —OCF 3 and —S(O) 0-2 (C 1 –C 6 )alkyl;

R 12 is H or C 1 –C 6 alkyl; and

R 13 is (C 1 –C 6 )alkyl-C(O)— or (C 1 –C 6 )alkyl-SO 2 —; comprising

(1) treating 2-amino-4,6-dihydroxypyrimidine

with POCl 3 in dimethylformamide to obtain 2-amino-4,6-dichloropyrimidine-5-carboxaldehyde

(2) treating carboxaldehyde VII with a hydrazide of the formula H 2 N—NH—C(O)—R, wherein R is as defined above, to obtain

(3) treating the intermediate of formula VIII with hydrazine hydrate to form a pyrazolo ring, thus obtaining the intermediate of formula IX

(4) forming the desired compound of formula II by dehydrative rearrangement.

2. A process for preparing a compound of the formula II

wherein R is R 1 -furanyl, R 1 -thienyl, R 1 -pyridyl, R 1 -pyridyl N-oxide, R 1 -oxazolyl, R 10 -phenyl, R 1 -pyrrolyl or C 4 –C 6 cycloalkenyl;

R 1 is 1 to 3 substituents independently selected from hydrogen, C 1 –C 6 -alkyl, —CF 3 , halogen, —NO 2 , —NR 12 R 13 , C 1 –C 6 alkoxy, C 1 –C 6 alkylthio, C 1 –C 6 alkylsulfinyl, and C 1 –C 6 alkylsulfonyl;

R 10 is 1 to 5 substituents independently selected from the group consisting of hydrogen, halogen, C 1 –C 6 alkyl, hydroxy, C 1 –C 6 alkoxy, —ON, —N H 2 , C 1 –C 6 alkylamino, di-((C 1 –C 6 )alkyl)amino, —CF 3 , —OCF 3 and —S(O) 0-2 (C 1 –C 6 )alkyl;

R 12 is H or C 1 –C 6 alkyl; and

R 13 is (C 1 –C 6 )alkyl-C(O)— or (C 1 –C 6 )alkyl-S 2 —; comprising converting a compound of formula IX

into the desired compound of formula II by dehydrative rearrangement.

3. A process for preparing a compound of formula IIIa

wherein R is R 1 -furanyl, R 1 -thienyl, R 1 -pyridyl, R 1 -pyridyl N-oxide, R 1 -oxazolyl, R 10 -phenyl, R 1 -pyrrolyl or C 4 –C 6 cycloalkenyl;

R 1 is 1 to 3 substituents independently selected from hydrogen, C 1 –C 6 -alkyl, —CF 3 , halogen, —NO 2 , —NR 12 R 13 , C 1 –C 6 alkoxy, C 1 –C 6 alkylthio, C 1 –C 6 alkylsulfinyl, and C 1 –C 6 alkylsulfonyl;

R 10 is 1 to 5 substituents independently selected from the group consisting of hydrogen, halogen, C 1 –C 6 alkyl, hydroxy, C 1 –C 6 alkoxy, —ON, —NH 2 , C 1 –C 6 alkylamino, di-((C 1 –C 6 )alkyl)amino, —CF 3 , —OCF 3 and —S(O) 0-2 (C 1 –C 6 )alkyl;

R 12 is H or C 1 –C 6 alkyl; and

R 13 is (C 1 –C 6 )alkyl-C(O)— or (C 1 –C 6 )alkyl-SO 2 —; comprising

(1) treating a chloride of formula VIII

with a hydroxyalkyl hydrazine of the formula HO—(CH 2 ) r —NHNH 2 , wherein r is 2–6, to obtain

(2) cyclizing the intermediate of formula X by dehydrative rearrangement to obtain the tricyclic intermediate of formula XI

(3) converting the hydroxy compound of formula XI to the bromide of formula IIIa.

Assignments (1)
CHANGE OF NAME Recorded Aug 30, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028884/0151 →